

1-1-2010


Definitions of the phenotypic manifestations of sickle cell disease.

Samir K Ballas
Thomas Jefferson University

Susan Lieff
Rho Federal Systems, Rho Inc.

Lennette J Benjamin
Department of Pediatrics, Montefiore Medical Center, Albert Einstein College of Medicine

Carlton D Dampier
Department of Pediatrics, Emory University, College of Medicine

Matthew M Heeney
Follow this and additional works at: <https://jdc.jefferson.edu/medfp>
Division of Pediatric Hematology/Oncology, Children's Hospital Boston
 Part of the [Medical Genetics Commons](#)

[Let us know how access to this document benefits you](#)
See next page for additional authors

Recommended Citation

Ballas, Samir K; Lieff, Susan; Benjamin, Lennette J; Dampier, Carlton D; Heeney, Matthew M; Hoppe, Carolyn; Johnson, Cage S; Rogers, Zora R; Smith-Whitley, Kim; Wang, Winfred C; and Telen, Marilyn J, "Definitions of the phenotypic manifestations of sickle cell disease." (2010). *Department of Medicine Faculty Papers*. Paper 38.
<https://jdc.jefferson.edu/medfp/38>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

Samir K Ballas, Susan Lieff, Lennette J Benjamin, Carlton D Dampier, Matthew M Heeney, Carolyn Hoppe, Cage S Johnson, Zora R Rogers, Kim Smith-Whitley, Winfred C Wang, and Marilyn J Telen

As submitted to:

American Journal of Hematology

And later published as:

“Definitions of the phenotypic manifestations of sickle cell disease”

Volume 85, Issue 1, January 2010, Pages 6-13

DOI: 10.1002/ajh.21550

Authors: Samir K. Ballas MD¹, Susan Lieff PhD², Lennette J. Benjamin MD³, Carlton D. Dampier, MD⁴, Matthew M. Heeney, MD⁵, Carolyn Hoppe, MD⁶, Cage S. Johnson, MD⁷, Zora R. Rogers, MD⁸, Kim Smith-Whitley, MD⁹, Winfred C. Wang, MD¹⁰, Marilyn J. Telen, MD¹¹, on behalf of the Investigators at the Comprehensive Sickle Cell Centers.

Affiliations:

¹ Department of Medicine, Cardeza Foundation for Hematologic Research, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA

² Rho Federal Systems, Rho Inc., Chapel Hill, NC

³ Department of Pediatrics, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY

⁴ Department of Pediatrics, Emory University College of Medicine, Atlanta, GA

⁵ Division of Pediatric Hematology/Oncology, Children's Hospital Boston, Boston, MA

⁶ Department of Hematology/Oncology, Children's Hospital Oakland, Oakland, CA

⁷ Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA

⁸ Division of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center Dallas, Dallas, Texas

⁹ Department of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA

¹⁰ Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN

¹¹ Division of Hematology, Duke University Medical Center, Durham, NC

Correspondence to: Karen Kesler, PhD
Rho, Inc.
6330 Quadrangle Drive, Suite 500
Chapel Hill, NC 27517
(919) 408-8000
(919) 408-0999 (fax)
kkesler@rhoworld.com

Abstract word count: 250

Body word count: 5627 (not including title page, abstract, and references)

Short running title: Phenotype Definitions in SCD

Keywords: Sickle cell disease, complications, phenotypes

Abstract: Sickle cell disease (SCD) is a pleiotropic genetic disorder of hemoglobin that has profound multi-organ effects. The low prevalence of SCD (~100,000/US) has limited progress in clinical, basic, and translational research. Lack of a large, readily accessible population for clinical studies has contributed to the absence of standard definitions and diagnostic criteria for the numerous complications of SCD and inadequate understanding of SCD pathophysiology. In 2005, the Comprehensive Sickle Cell Centers initiated a project to establish consensus definitions of the most frequently occurring complications. A group of clinicians and scientists with extensive expertise in research and treatment of SCD gathered to identify and categorize the most common complications. From this group, a formal writing team was formed that further reviewed the literature, sought specialist input, and produced definitions in a standard format. This manuscript provides an overview of the process and describes twelve body system categories and the most prevalent or severe complications within these categories. A detailed Appendix provides standardized definitions for all complications identified within each system. This report proposes use of these definitions for studies of SCD complications, so future studies can be comparably robust and treatment efficacy measured. Use of these definitions will support greater accuracy in genotype-phenotype studies, thereby achieving a better understanding of SCD pathophysiology. This should nevertheless be viewed as a dynamic rather than final document; phenotype descriptions should be reevaluated and revised periodically to provide the most current standard definitions as etiologic factors are better understood and new diagnostic options are developed.

Introduction

Sickle cell disease (SCD) is an inherited disorder due to homozygosity for the sickle β -globin gene mutation at position 6 (glu \rightarrow val), or double heterozygosity for the sickle gene and another mutation for a different hemoglobin variant or one of numerous β -thalassemia mutations. SCD is a systemic pleiotropic disease that affects nearly all organs during the life of afflicted patients. Specific phenotypic manifestations of the disease are protean in nature and vary considerably in frequency and severity latitudinally among patients and longitudinally in the same patient over time.

The lack of universally accepted nomenclature and diagnostic criteria for the complications of SCD has been confusing to patients, their families, the public, and providers, and has hampered clinical research efforts to collect outcome data and compare research methods and findings. This report defines selected complications of SCD in a uniform manner, drawing on recently published literature and the expertise of a broad variety of active clinicians and investigators. The goals are to provide current consensus definitions of the phenotypic manifestations of SCD and to facilitate research by establishing a common basis for comparison of data.

Therefore, this paper describes the complications that are particularly characteristic of SCD and are due to the sequence of events that result from the pathophysiologic biology of the abnormal sickle red cell. These complications are placed within one of twelve broad categories classified according to basic system/organ involvement and are represented by bold headings. Ten specific complications have been selected for discussion in detail due to their relative frequency and/or potential severity, and are indicated by underlined subheadings within the appropriate category sections. In addition, controversies regarding these complications are discussed. The formal definitions for these complications are included in an accompanying Appendix.

The Appendix, available online at this journal's website, includes all 62 selected complications listed within their respective categories, including those unique to SCD and those that are secondary in nature or due to co-morbidities. The Appendix includes the following for each complication: Definition, Diagnostic Criteria, Severity Index, Classification, and References. The purpose of the Appendix is to provide practitioners and investigators with a concise reference describing the major features of each complication and its associated diagnostic tests and, where applicable, measures of severity.

The description of each complication is evidence-based whenever possible. For some complications, no published evidence or standard was found for the Severity Index and/or the Classification. In some situations, the authors have recommended descriptions based on the vast experience of experts in SCD and have noted the descriptions as such.

Methods

Background

The Statistics and Data Management Center (SDMC) of the National Heart, Lung, and Blood Institute (NHLBI) Comprehensive Sickle Cell Centers (CSCC) Program was charged in 2003 with establishing a database of clinical, quality of life, and outcomes data to support development of multi-center research on SCD. A committee composed of representatives from 5 of the 10 participating clinical centers (C-Data Protocol Committee) assisted the SDMC in developing a protocol for this Collaborative Data Project (C-Data). The SDMC and C-Data Protocol Committee created a detailed case report form (CRF) designed to obtain comprehensive clinical, surgical, hospitalization, and laboratory data from medical record review to focus data collection on those features considered most important and most useful in identifying potential subjects for future trials. However, the lack of standard, universally applied definitions for clinical conditions or phenotypes used in the context of SCD initially threatened to make the collection of uniform data from existing medical records across sites impractical and likely impossible. Therefore, the Committee recommended initiation of a formal effort to establish standardized definitions for use in C-Data prospective data collection, CSCC future studies, and SCD research in general.

In parallel with this effort, an NIH-sponsored conference, "New Directions for Sickle Cell Therapy in the Genome Era", listed as its highest priority the establishment of a SCD network that would include a comprehensive patient database and a biological sample repository to support examination of phenotypic diversity and serve as a resource for future research. As a result, the CSCC Center Directors, with support from the NHLBI, endorsed expansion of the C-Data Project to include the collection, testing, and storage of blood and DNA samples from participants. Based on this decision and the earlier recommendation of the C-Data Protocol Committee, the CSCC Steering Committee approved formation of an ad hoc work group to establish consensus definitions of the phenotypic manifestations of SCD.

Preliminary and Work Group Activities

The work group was composed of 16 clinicians and scientists with extensive expertise in research and treatment of SCD, representing the ten clinical centers and the SDMC, and chaired by Dr. Marilyn Telen of Duke University Medical Center. Dr. Lieff and the SDMC staff established several tools prior to the meeting to facilitate the group's work. A list of complications, based on literature on SCD and complications already included in the C-Data medical history CRF, was compiled by the SDMC and further refined by the C-Data Protocol Committee and the CSCC Program Medical Monitor. A draft format or schema was developed to provide a standardized approach to writing the definitions. Group members were assigned to one of six subgroups based on their expertise. Each subgroup was given a small set of complications and asked to prepare preliminary draft definitions for their complications set, with the goal of having good familiarity with the most recent literature and the real variation in

interpretation and application of a diagnosis for a given complication. Work group members received this information 2 weeks in advance and were asked to provide feedback prior to the meeting.

The 2-day meeting began with a large group discussion of the history, rationale, and goals of the CSCC's priority effort to develop standardized phenotype definitions. Subgroups then received the set of draft definitions for their assigned complications, which had been revised based on member responses submitted previously. The subgroups met separately to rewrite or refine the definitions. Groups were asked to include what most experts accept as a definition of the complication in question, as well as the supporting diagnostic criteria or measurements needed to confirm the diagnosis. If appropriate, levels of certainty for the diagnosis were to be indicated; an MRI for example, may be considered the "gold standard" for determination of a cerebrovascular accident (CVA), whereas a neurological exam is viewed with less certainty.

The large group reconvened to review the subsequent drafts and provide feedback. This process was repeated a second time. At the final group session, some definitions were excluded and a few added, remaining questions for specific complications identified, and plans made to finalize the set of definitions for submission to the Steering Committee for approval.

The C-Data Protocol Committee met to compare the work group's approved draft definitions to the list of complications captured in C-Data at that time, and revised the definitions further. This group modified the CRFs designed to collect prospective clinical data, to accommodate the revised phenotype definitions. The final CRFs were approved in June 2006. Final revisions of definitions continued; they were approved by the Steering Committee in July 2007.

A group of CSCC investigators committed to establishing a final, workable set of phenotype definitions for use within the CSCC program and in the SCD research community formed a writing group to develop a publishable document that would be available to the widest audience possible. This group, led by Dr. Samir Ballas of Thomas Jefferson University, determined the goals and structure of the manuscript, and identified the most appropriate site for publication. The authors decided the best approach was to provide an overview of the process, a description of the 12 body system categories, a description of the most relevant or severe complications within these categories, and to provide the standardized definitions for all complications in an Appendix. A manuscript proposal was submitted to and approved by the CSCC Publications Committee. Professional medical writers and editors were involved in the writing and editing process to ensure the presence of a logical, standard, and consistent style readily accessible and understood by the broad target audience. The writing group worked consistently during the year and a half preceding manuscript submission to successfully accomplish these goals, which offer a potentially important contribution to SCD research.

Complications of Sickle Cell Disease

Major clinical manifestations of SCD include three sets of signs and symptoms: 1) hemolytic anemia and its sequelae as shown in Table 1; 2) pain syndromes and related issues as shown in Table 2; 3) complications affecting major organs and their sequelae as shown in Table 3. Definitions of these complications are described below and/or in the Appendix. Co-morbid conditions associated with SCD will not be defined in this paper, though some of the relatively common co-morbid conditions are defined in the Appendix.

Acute Exacerbations of Anemia

Sickle cell disorders are associated with variable degrees of anemia depending on genotype, with the most severe decrease in hemoglobin level seen in sickle cell anemia (homozygous hemoglobin S) and the least severe decrease in hemoglobin S- β^+ thalassemia. After the first five years of life, the hemoglobin concentration in an individual patient usually remains constant in the steady state over time. However, clinically significant acute lowering of the hemoglobin concentration below steady state values does occur episodically. These episodes may result from a variety of causes, including hyperhemolysis, acute splenic sequestration, and aplastic crises. Characteristics of these episodes are described in the Appendix and briefly discussed below. It is important to understand the use of diagnostic tests in the differentiation of these causes of exacerbation of anemia, since appropriate treatment is different for each of them.

Hyperhemolysis

Although chronic hemolytic anemia is a major feature of sickle cell disorders, a marked drop in hemoglobin with evidence of an increased hemolytic rate is referred to as hyperhemolysis. Hyperhemolysis is ordinarily diagnosed when the exacerbation of anemia occurs in the absence of other identifiable causes of red cell destruction (eg, splenic or hepatic sequestration). It is most often, but not always, accompanied by evidence of increased red blood cell production (increased reticulocytosis). Several sub-phenotypes of hyperhemolysis arising from different pathophysiologic mechanisms may complicate the clinical course of sickle cell disorders. One type is related to acute or delayed hemolytic transfusion reactions, in which hemolysis may occur due to the "innocent bystander mechanism."¹ In the innocent bystander mechanism, both autologous and homologous red cells (RBCs) are destroyed. It is typically, although not uniformly, associated with a paradoxical decrease in reticulocyte count. In hemolytic transfusion reactions, homologous (transfused) RBCs are destroyed, presumably due to interaction with alloantibodies. A positive direct antiglobulin (or Coombs) test is usually but not uniformly present. Recognition of the hyperhemolysis syndrome is especially important, as hemoglobin levels often decrease further with transfusion, even when crossmatch-compatible blood is provided.¹

Another type of hyperhemolysis in SCD is not related to blood transfusion but is an independent complication of the disease itself, in which autologous RBCs are destroyed at an increased rate in the presence or absence of an acute painful crisis. Isolated episodes of hyperhemolysis in the absence of painful crises are often referred to as hemolytic crises.ⁱⁱ Hyperhemolysis may also be drug induced.

It should be noted that a diagnosis of hyperhemolysis in the post-transfusion setting can be made only by calculation of the destruction of transfused and autologous red blood cells using results of serial blood counts, reticulocyte counts, and hemoglobin electrophoresis.

Acute Splenic Sequestration

Acute splenic sequestration was first recognized in 1945ⁱⁱⁱ and is one of the leading causes of death in children with sickle cell anemia.^{iv,v,vi} In patients homozygous for hemoglobin S, the lifetime prevalence of acute splenic sequestration has been reported to be between 7% and 30%.^{vii,viii} It can occur as early as 8 weeks of age^{ix}, though more typically an initial event occurs in the toddler age group. Patients with hemoglobin SC or hemoglobin S/ β -thalassemia tend to have a first event later in life, even into adulthood.^{x,xi} Although acute splenic sequestration is often associated with an infectious trigger, it may also be unprovoked.^{viii,xii}

Acute splenic sequestration is characterized by a tender, rapidly enlarging, and sometimes massive spleen due to the trapping of sickle erythrocytes and other blood constituents and may lead to shock due to loss of effective circulating volume. The hemoglobin concentration decreases from baseline by at least 2 g/dL, usually with evidence of reticulocytosis and often moderate to severe thrombocytopenia. Prompt recognition of acute splenic sequestration is critical to the provision of appropriate and timely therapy of this life-threatening complication.

Aplastic Crises

Since SCD patients rely on constant overproduction of RBCs to maintain even their baseline low hemoglobin levels, any process that interferes with erythropoiesis can result quickly in severe anemia. Erythropoiesis can be suppressed by almost any infectious or inflammatory process to some degree, but occasionally severe transient red cell aplasia (absolute reticulocyte count <50,000/ul) occurs, leading swiftly to severe anemia. Among infectious causes, parvovirus B19 infection classically causes the most severe reticulocytopenia, often to levels <20,000/ul.^{xiii}

Cardiac Complications

Sickle cell disorders are associated with multiple clinically significant cardiac abnormalities, primarily but not exclusively in adults. The anemia of SCD is associated with a chronic high cardiac output state, the physiological sequelae of which are not completely understood. Morphologic and physiologic changes include a thickened interventricular septum, increased left ventricular mass, abnormal left ventricular diastolic filling, and left ventricular diastolic dysfunction,

among others. Electrocardiograms often provide signs of left ventricular hypertrophy and demonstrate nondiagnostic ST and T wave abnormalities, as well as conduction abnormalities. Increased preload and decreased afterload help maintain a normal or high ejection fraction despite these abnormalities, unless and until decompensation occurs. The impact of these cardiac findings is not clearly delineated, but they have been proposed to affect oxygen transport and delivery and may also contribute to the relatively high incidence of sudden death among SCD patients. Cardiac dysfunction also potentially has implications for other end-organ functions.

Disturbances of Growth and Development

Children with sickle cell disorders have significantly decreased height, weight, and body mass index (BMI), as well as delayed sexual maturation, when compared with control subjects.^{xiv} Inadequate nutrition, abnormal endocrine function, and, in particular, increased caloric requirements due to elevated energy expenditure may all be etiologic factors. Although definitive evidence is lacking, growth may be enhanced by chronic transfusion, increased caloric intake, or hydroxyurea. In order to evaluate the effects of interventions on growth in persons with sickle cell disorders, comparison with standardized growth charts, such as those from the US National Center for Health Statistics (NCHS), may be utilized, with growth expressed as Z-scores (the number of standard deviations below or above the “normal” mean for age).

Gastrointestinal/Hepatobiliary Complications

Hepatobiliary pathology in sickle cell disorders is common but not always related specifically to the underlying SCD. For example, the definitions presented in the Appendix for cholecystitis, cholelithiasis, pancreatitis, and viral hepatitis are not unique to sickle cell disorders, although their incidence may be more common in this group than in the general population. Hepatic sequestration and intrahepatic cholestasis, however, are virtually unique to sickle cell disorders, and their definitions are of specific interest to hematologists.

Acute Hepatic Sequestration / Intrahepatic Cholestasis

Sequestration of red cells and other blood cells may also take place in the liver, either in isolation or in combination with splenic sequestration. Tender, progressive hepatomegaly, accentuated anemia below baseline, reticulocytosis, and hyperbilirubinemia are the usual clinical features of hepatic sequestration and can mimic acute cholecystitis or viral hepatitis, although sequestration usually is accompanied by less pronounced transaminitis and lack of elevation of pancreatic enzymes.^{xv,xvi,xvii} Hepatic sequestration is not usually life-threatening, because the liver is not as distensible as the spleen and therefore pooling of red blood cells is rarely significant enough to cause cardiovascular collapse. However, it can lead to decreased liver function and, like splenic sequestration, usually responds to transfusion. Intrahepatic cholestasis (ie, obstruction of bile formation or flow) can

occur in the setting of hepatic sequestration, leading not only to hyperbilirubinemia but also to striking hepatic dysfunction, with marked deterioration of synthetic function. Blood exchange transfusion is often needed for intrahepatic cholestasis.

Muscular/Skeletal/Skin Complications

Dactylitis, avascular necrosis, leg ulcers, osteomyelitis, osteopenia, and osteoporosis are frequent in patients with sickle cell disorders. The clinical features are similar to those in individuals without SCD, but the age at presentation is earlier and the response to interventions, when required, is poor. Musculoskeletal and dermatologic complications are often due to vaso-occlusion, but hemolysis, infection, and chronic co-morbidities can have detrimental consequences if not addressed. Swelling, erythema, and fever can occur from cell death due to hemolysis. Patients with dactylitis, bone infarction, or leg ulcers develop pain at the involved site, but swelling, erythema, and fever may occur, implying the possibility of infection as an underlying or complicating feature. When recurrent leg ulcers and myositis develop, co-morbidities such as diabetes and rheumatologic conditions such as systemic lupus erythematosus should be considered.

Neurologic Complications

The effects of sickle cell disorders on the brain vary with age, may be acute or chronic, may be clinically overt or subtle (“silent”), and may result in significant morbidity and even mortality. The underlying cerebrovascular lesions also vary from extensive, large vessel distribution infarcts to the “silent” infarcts associated with microvascular disease. Central nervous system lesions may be infarctive due to vaso-occlusion, hemorrhage, or both.

Cerebrovascular Accident

Cerebrovascular accident (CVA) was previously defined by the CSSCD as an acute neurological syndrome secondary to occlusion of an artery or hemorrhage, with resultant ischemia and neurologic signs and symptoms. A small fraction of the strokes in children, but the majority of those in adults, are hemorrhagic, with intraventricular, intracerebral, or subarachnoid bleeding. Like the previous Cooperative Study of Sickle Cell Disease (CSSCD) definitions for cerebrovascular complications, the symptomatic manifestations of stroke rely on physical exam findings but have been modified to include evidence-based practice and imaging techniques to objectively confirm brain lesions and vascular pathology. The availability of diffusion-weighted intensity (DWI) MRI has facilitated the early detection of acute ischemia and provides an objective measure by which to define and classify stroke subtypes. Noninvasive imaging by MRA is now routinely used to document stenosis or obstruction of flow in the large intracranial vessels, as well as abnormal vessel formation, including moyamoya, and correlates well with standard angiography.

The use of transcranial Doppler (TCD) ultrasonography to identify sickle cell patients at increased risk for stroke was introduced in the early 1990s, validated in a series of studies, and demonstrated in the STOP trial (a phase III randomized, prospective, multicenter clinical trial of chronic transfusion versus standard observation) to be remarkably useful in identifying patients at risk for this devastating complication.^{xviii} We have adopted the definitions for normal, conditional (borderline), and abnormal TCD velocities used in the STOP studies: time-averaged mean of the maximum velocity in the middle cerebral or distal carotid artery <170, 170-199, and ≥ 200 cm/sec, respectively. An important part of the definition is that TCD studies should be performed in patients under steady-state conditions by an experienced technologist.

Transient Ischemic Attacks

Transient ischemic attacks (TIAs) are relatively infrequent events in persons with sickle cell disorders, but their occurrence indicates an increased risk for overt stroke. Until recently, TIA was defined by neurologic dysfunction caused by focal brain ischemia with symptoms lasting *up to 24 hours*, but recent neurology literature has utilized a period of symptomatology that is typically less than 1 hour.^{xix} Resolution of neurologic symptoms and a lack of lesions in the region corresponding to symptoms on neuroimaging are also elements in the current definition of TIA.

Silent Cerebral Infarcts

Silent cerebral infarcts were initially described in the CSSCD based on brain MRI findings in children with normal neurologic examinations.^{xx} Subclinical infarcts detected by MRI are actually not “silent,” since we now know that they are associated with neurocognitive deficits (and an increased risk for overt stroke). An important part of this definition is that these lesions cannot be attributed to an overt neurologic event or finding.

Ophthalmologic Complications

Ophthalmologic complications of sickle cell disorders are relatively common and may occur in any vascular bed of the eye. Sickle cell eye disease may be insidious in nature and may not be detected at its early stages unless an eye exam is performed annually. Annual eye examinations in this population should include an accurate measurement of visual acuity and intraocular pressure, examination of the anterior structures of the eye using a slit lamp biomicroscope, and examination of the posterior structures of the eye, including the retina, through dilated pupils and using fluorescein angiography. In general, diagnostic criteria for SCD patients are the same as for causes of ocular pathology in other populations.

Pain Syndromes

Sickle cell pain is unique in that it occurs as a hallmark feature in a genetic disorder as early as infancy and throughout a lifetime. SCD-associated pain can be acute, subacute, chronic, or episodic. Patients may experience somatic, visceral, neuropathic, or even iatrogenic pain. While pain is most often spontaneous, it is occasionally evoked, but rarely psychogenic. Sickle cell pain syndromes vary in character and intensity depending on the location and severity of tissue damage. Symptom intensity and duration are influenced by a variety of biochemical, neurological, psychosocial, cultural, spiritual, and environmental factors that may be further modified by disease or treatment-related effects. No diagnostic tests are currently available to define the extent, location, or severity of tissue damage from vaso-occlusion. Categorization of pain syndromes thus relies on careful clinical histories and examinations, as well as the clinical context of the pain symptoms. The pain syndromes described reflect the result of the primary disease process and resultant tissue damage (acute sickle cell pain, multi-organ system failure), pain characteristics related to nerve damage or neuronal dysfunction (neuropathic pain), or consequences of treatment (iatrogenic pain syndromes).

Vaso-occlusive Episodes

Pain from tissue ischemia as a result of vaso-occlusion is the most common complication of SCD.^{xxi,xxii,xxiii,xxiv,xxv} Vaso-occlusion may occur in a variety of vascular beds, but those in the deep muscle, periosteum, and bone marrow appear to be most often affected.^{xxv} These same tissues are also richly innervated by nociceptors activated by a variety of inflammatory mediators.^{xxi,xxvi} Recurrent episodes of acute pain (painful crises) lasting for hours to days (or rarely weeks), begin early in childhood and often become more frequent in adolescents and adults, who additionally may display variable degrees of persistent pain related to chronic bone and joint damage.^{xxi,xxii,xxiii,xxvii,xxviii} Neurological changes in response to persistent pain can lead to an enhanced sensitivity to pain, and psychosocial sequelae can increase subsequent suffering.^{xxi,xxii,xxiii,xxvi}

As pain symptoms are in part a reflection of disease activity, a better understanding of disease pathogenesis is an important aspect of sickle pain management. Thus the acute painful episode (painful crisis) evolves through four phases: prodromal, initial, established, and resolving.^{xxix} Objective laboratory signs do occur during these phases in most patients, provided they are done serially and compared to established steady-state values. Moreover, recent studies have suggested a vaso-occlusive “phenotype” consisting of patients with relatively higher hemoglobin levels who clinically display increased frequency of pain, acute chest syndrome, and avascular necrosis.^{xxx}

Pulmonary Complications

Individuals with sickle cell disorders have a unique pathophysiology that puts the microvasculature of the lung at particular risk for complications. Acute chest syndrome is unique to sickle cell syndromes, and physicians must be aware of

the potential for rapid progression that may prove fatal in the child or adult with sickle cell disorders. Pulmonary hypertension is very common in persons with sickle cell disorders and is probably related at least in part to chronic hemolysis and nitric oxide consumption, as it occurs in other hemolytic anemias as well. The diagnostic criteria required to define pulmonary hypertension are distinct for sickle cell disorders. However, chronic obstructive and restrictive pulmonary disease, asthma, obstructive sleep apnea, and pulmonary embolism are not unique to patients with sickle cell disorders and are defined as in unaffected individuals. The hypoxia caused by these conditions affects hemoglobin S polymerization as well as other aspects of sickle red cell biology and may therefore accelerate the microvascular complications of SCD. This pathophysiology requires the caregiver to be cognizant of these potentially deleterious consequences. Recognition of pulmonary embolism is particularly difficult in SCD patients. The recurrent chest or rib pain that is often reported in sickle cell disorders may make recognition and diagnosis of non-sickle pulmonary conditions such as pulmonary embolism difficult. The paragraphs below list features that may be helpful to diagnose these conditions.

Acute Chest Syndrome

The term acute chest syndrome (ACS) reflects the difficulty in distinguishing pulmonary infection (viral or bacterial pneumonia) from other conditions that may occur in SCD, including inflammatory changes following pulmonary fat embolism or pulmonary infarction by microvascular occlusion or thromboembolism. Bacterial infection is diagnosed by culture of a respiratory pathogen from sputum or blood, but such cultures are negative in the majority of ACS cases. The diagnosis of fat embolism can be established by bronchoalveolar lavage (BAL) with examination for lipid-laden macrophages, but while BAL has a higher bacterial culture yield,^{xxxii} it is clinically impractical in most instances. Finally, distinguishing thromboemboli from microvascular occlusion using chest tomography or lung scintigraphy is difficult, as the findings are nearly identical.^{xxxiii} Consequently, the historical term ACS cannot be discarded until better diagnostic testing becomes available.

Acute chest syndrome clinically and radiologically resembles bacterial pneumonia. However, the clinical course of ACS in persons with sickle hemoglobinopathies is considerably different from that of pneumonia in hematologically normal individuals. Multiple lobe involvement and recurrent infiltrates are more common in SCD, and the duration of clinical illness and of radiologic clearing of infiltrates may be prolonged to 10 days or longer.^{xxxiv,xxxv} Acute pulmonary infiltrates are particularly difficult to classify in sickle cell disorders because of the potential for rapid progression from mild hypoxia to pulmonary failure, acute respiratory distress syndrome (ARDS), and multiorgan failure as a consequence of disseminated microvascular occlusion. Any decline in arterial oxygen saturation increases the fraction of polymerized Hb S with a subsequent deleterious effect on blood flow and pulmonary function.

ACS is associated with considerable morbidity and both acute and delayed mortality. The incidence is highest in children 2 to 4 years of age and, while gradually declining with age, remains common in adults.

Pulmonary Hypertension

Pulmonary hypertension (pHTN) has been recognized as an increasingly common and deadly complication of sickle cell disorders,^{xxxvi,xxxvii,xxxviii} as well as other hemolytic anemias.^{xxxix} Approximately 40% of adults with SCD can be identified as having pHTN; similar proportions are seen in pediatric and adolescent patient populations. In contrast to primary pHTN, however, pHTN in SCD tends to exhibit lower pulmonary artery pressures but nevertheless is associated with increased mortality. Adult SCD patients with pHTN have a 6- to 10-fold higher risk of mortality than do SCD patients without pHTN; however, the risk in the pediatric age group is less well defined. In most studies, pHTN in SCD has been defined by the presence of a tricuspid regurgitant jet velocity (TRjet) of ≥ 2.5 m/s. Although this criterion has correlated with markedly reduced survival in a number of studies, this diagnostic threshold, though arbitrary, is commonly used and corresponds to a pulmonary arterial (PA) systolic pressure of approximately 30 mmHg. When right heart catheterization is done, pulmonary artery hypertension is considered present when the mean PA pressure is ≥ 25 mmHg. In addition, many investigators now feel that SCD patients with pHTN belong to a subset of patients with a “high hemolytic rate” phenotype.^{xi} In addition to having lower hemoglobin and higher lactate dehydrogenase (LDH) levels at baseline,^{xxxvi,xli} patients with pHTN are now also recognized to have other sequelae of SCD at higher rates than patients without pHTN. Patients with pHTN exhibit a higher prevalence of proteinuria and decreased glomerular filtration rate (GFR),^{xxxviii} as well as left ventricular (usually diastolic) dysfunction, leg ulcers, and CNS events.^{xli} Finally, we do not fully understand the mechanism and rate of the development of pHTN, especially the hypothesized transition from initially reversible pulmonary arterial vasoconstriction to more fixed and irreversible vasculopathy.

Renal/Genitourinary Complications

Renal complications such as hematuria, proteinuria, pyelonephritis, acute renal failure, and chronic renal insufficiency are more common and occur at earlier ages in persons with sickle cell disorders compared with individuals without SCD. The underlying pathology may be due to the complication of intravascular hemolysis or infarction of tissue beyond a vessel blocked by hemoglobin S red cells. Also, once a condition develops, it may recur or progress more rapidly in SCD patients. Nevertheless, renal complications are defined and managed in a fashion similar to conditions in individuals without SCD. However, the initial hyperfiltration typical in persons with sickle cell disorders results in a lower serum creatinine, so the definition of renal insufficiency is modified accordingly.

Splenic Complications

Splenic pathology in sickle cell disorders is related to the organ's unique interaction with the sickle erythrocyte and subsequent physiologic dysfunction. The relatively hypoxic and acidic splenic environment favors erythrocyte sickling and vaso-occlusion. Intrasplenic vaso-occlusion can be acute, resulting in life-threatening splenic sequestration (see discussion under Acute Exacerbations of Anemia), or chronic, leading to splenic enlargement and hypersplenism with peripheral cytopenias. Vaso-occlusion can lead to an acutely painful infarction of the organ but more commonly results in repeated minor subclinical episodes and gradual loss of splenic phagocytic and immunologic function in early childhood. This functional hyposplenism/asplenia in turn results in increased susceptibility to sepsis, particularly from encapsulated bacteria.

Transfusions and Iron Overload

Patients with SCD receive transfusions for multiple acute and chronic complications during their lifetimes, predisposing them to iron overload and alloimmunization, even when they are not on chronic transfusion regimens. While blood tests such as ferritin and transferrin saturation are helpful in identifying patients with risk for iron-mediated tissue damage, they are unreliable indicators of the degree of tissue hemosiderosis. Liver iron analysis is the most reliable assessment of iron load, but requires a liver biopsy. Other assessments of liver iron, such as SQUID and MRI T2*, are also reliable and less invasive, but not yet widely accessible. For these reasons, as well as the lack of a carefully performed prevalence study, the degree to which iron overload shortens average life expectancy for patients with SCD is unclear.

Alloimmunization, including the production of multiple alloantibodies, is common after transfusion in SCD. Since most SCD patients in the US are African-American, while most blood donors are Caucasian, efforts to prevent alloimmunization are widely recommended, most often through the provision of C-, E-, K- red cells to SCD patients negative for these antigens. Moreover, there is a relatively high frequency of delayed hemolytic transfusion reactions in SCD. It is important to recognize the unique features such reactions can have in SCD, especially the associated vaso-occlusive symptoms and the phenomenon of hyperhemolysis, discussed above. Autoantibodies and reticulocytopenia may also be found in this setting. Therefore, the clinician must be aware that further transfusion, even of antigen-matched and crossmatch-compatible blood, may result in further exacerbation of anemia and lead to a fatal outcome.

Summary

Provision of clinical care and performance of clinical research in SCD have been hampered not only by the relatively low prevalence of the disease (<100,000 persons in the US) but also by the lack of clear definitions and diagnostic criteria for the myriad complications of SCD and the burgeoning but still inadequate understanding of SCD pathophysiology. This report therefore proposes definitions for the most frequently observed complications of SCD, so that future research studies can be used to validate study results and efficacy of treatment can be measured. We believe that these definitions will facilitate future genotype-phenotype studies that promise to increase understanding of the pathophysiology of SCD complications. It is the hope of those who supported and contributed to this project that this manuscript will be viewed as a dynamic document. A high priority should be given to reevaluation and revision of the phenotype definitions at periodic intervals to ensure the most current and standardized definitions are available, as better etiologic understandings emerge and new diagnostic and treatment options are developed.

Acknowledgements

NIH Support

Development of standard phenotype definitions was supported by the National Heart, Lung, and Blood Institute via Award Number U54HL070587. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. Dr. Greg Evans was the Project Officer for this effort.

Comprehensive Sickle Cell Centers

Boston Comprehensive Sickle Cell Center, Boston, MA

Bronx Comprehensive Sickle Cell Center, Bronx, NY

Children's Hospital of Philadelphia, Philadelphia, PA

Cincinnati Comprehensive Sickle Cell Center, Cincinnati, OH

Duke-UNC Comprehensive Sickle Cell Center, Durham, NC

Marian Anderson Sickle Cell Anemia Care and Research Center, Philadelphia, PA

Northern California Comprehensive Sickle Cell Center, Oakland, CA

St. Jude's Children's Research Hospital Comprehensive Sickle Cell Center, Memphis, TN

University of Southern California Comprehensive Sickle Cell Center, Los Angeles, CA

University of Texas Southwestern Comprehensive Sickle Cell Center, Dallas, TX

Statistical and Data Coordinating Center

Rho Federal Systems of Rho, Inc. in Chapel Hill, NC provided the leadership for the planning and organizational support for this effort, including facilitation, communication, writing, editing, and administration. Susan Lieff, PhD, and Karen Kesler, PhD, served as principal investigators of the coordinating center.

Other Contributors

Karen Kalinyak, MD, Cincinnati Children's Hospital; Henry Adewoye, MD, Boston University; Ward Hagar, MD, Children's Hospital Oakland; Rupa Redding-Lallinger, MD, University of North Carolina at Chapel Hill; Janet Kwiatkowski, MD, Children's Hospital of Philadelphia; Catherine Driscoll, MD, Montefiore Medical Center; Clinton Joiner, MD, PhD, Cincinnati Children's Hospital; Morton Goldberg, MD, Johns Hopkins University; Gerald Luty, PhD, Johns Hopkins University; Laura Svetkey, MD, Duke University Medical Center; Marsha

McMurray, Rho, Inc.; Catherine Snyder, Rho, Inc.; Russ Barnes, Rho, Inc.; Terri O'Quin, Consultant to Rho, Inc.; Greg Evans, PhD, Project Office at NHLBI.

References

- ⁱ Petz LD, Calhoun L, Shulman IA, et al. The sickle cell hemolytic transfusion reaction syndrome. *Transfusion* 1997;37:382–92.
- ⁱⁱ Ballas SK, Marcolina MJ. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. *Transfusion* 2006;46:105–110.
- ⁱⁱⁱ Tomlinson WJ. Abdominal crises in sickle cell anemia: a clinicopathological study of eleven cases with a suggested explanation of their cause. *Am J Med Sci* 1945;209:722–741.
- ^{iv} Mancini EA, Culbertson DE, Yang YM, et al. Causes of death in sickle cell disease: an autopsy study. *Br J Haematol* 2003;123:359–365.
- ^v Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. *Blood* 1995;86:776–783.
- ^{vi} Leikin SL, Gallagher D, Kinney TR, et al. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. *Pediatrics* 1989;84:500–508.
- ^{vii} Kinney TR, Ware RE, Schultz WH, et al. Long-term management of splenic sequestration in children with sickle cell disease. *J Pediatr* 1990;117:194–199.
- ^{viii} Emond AM, Collis R, Darvill D, et al. Acute splenic sequestration in homozygous sickle cell disease: natural history and management. *J Pediatr* 1985;107:201–206.
- ^{ix} Pappo A, Buchanan GR. Acute splenic sequestration in a 2-month-old infant with sickle cell anemia. *Pediatrics* 1989;84:578–579.
- ^x Solanki DL, Kletter GG, Castro O. Acute splenic sequestration crises in adults with sickle cell disease. *Am J Med* 1986;80:985–990.
- ^{xi} Orringer EP, Fowler VG Jr, Owens CM, et al. Case report: splenic infarction and acute splenic sequestration in adults with hemoglobin SC disease. *Am J Med Sci* 1991;302:374–379.
- ^{xii} Seeler RA, Shwiaki MZ. Acute splenic sequestration crises (ASSC) in young children with sickle cell anemia. Clinical observations in 20 episodes in 14 children. *Clin Pediatr (Phila)* 1972;11:701–704.
- ^{xiii} Eichhorn RF, Buurke EJ, Blok P, et al. Sickle cell-like crisis and bone marrow necrosis associated with parvovirus B19 infection and heterozygosity for haemoglobins S and E. *J Intern Med* 1999;245:103–106.
- ^{xiv} Platt OS, Rosenstock W, Espeland MA. Influence of sickle hemoglobinopathies on growth and development. *N Engl J Med* 1984;311:7–12.
- ^{xv} Hatton CS, Bunch C, Weatherall DJ. Hepatic sequestration in sickle cell anaemia. *Br Med J (Clin Res Ed)* 1985;290:744–745.
- ^{xvi} Hernández P, Dorticós E, Espinosa E, et al. Clinical features of hepatic sequestration in sickle cell anaemia. *Haematologia (Budap)* 1989;22:169–174.
- ^{xvii} Sheehy TW. Sickle cell hepatopathy. *South Med J* 1977;70:533–538.
- ^{xviii} Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. *N Engl J Med* 1998;339:5–11.
- ^{xix} Albers GW, Caplan LR, Easton JD, et al. Transient ischemic attack—proposal for a new definition. *N Engl J Med* 2002;347:1713–1716.
- ^{xx} Moser FG, Miller ST, Bello JA, et al. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. *AJNR Am J Neuroradiol* 1996;17:965–972.
- ^{xxi} Ballas SK. Sickle cell pain. *Progress in pain research and management*. Vol 11. Seattle, WA: IASP Press; 1998.
- ^{xxii} Benjamin LJ. Nature and treatment of the acute painful episode in sickle cell disease. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, editors. *Disorders of hemoglobin: genetics, pathophysiology, and clinical management*. Cambridge: Cambridge University Press; 2001. p 671–710.
- ^{xxiii} Serjeant GR. *Sickle cell disease*. 3rd ed. New York: Oxford University Press; 2001.
- ^{xxiv} Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: rates and risk factors. *N Engl J Med* 1991;325:11–16.
- ^{xxv} Frenette PS. Sickle cell vaso-occlusion: multistep and multicellular paradigm. *Curr Opin Hematol* 2002;9:101–106.
- ^{xxvi} Benjamin LJ, Payne R. Pain in sickle cell disease: a multidimensional construct. In: Pace B, editor. *Renaissance of sickle cell disease research in the genome era*. London: Imperial College Press; 2007. p 99–118.

-
- ^{xxvii} Dampier C, Setty BN, Eggleston B, et al. Vaso-occlusion in children with sickle cell disease: clinical characteristics and biologic correlates. *J Pediatr Hematol Oncol* 2004;26:785–790.
- ^{xxviii} Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology and prognostic significance. *Am J Hematol* 2005;79:17–25.
- ^{xxix} Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. *Blood* 1992;79:2154–2163.
- ^{xxx} Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. *Blood Rev* 2007;21:37–47.
- ^{xxxi} Maitre B, Habibi A, Roudot-Thoraval F, et al. Acute chest syndrome in adults with sickle cell disease: therapeutic approach, outcome, and results of BAL in a monocentric series of 107 episodes. *Chest* 2000;117:1386–1392.
- ^{xxxii} Bhalla M, Abboud MR, McLoud TC, et al. Acute chest syndrome in sickle cell disease: CT evidence of microvascular occlusion. *Radiology* 1993;187:45–49.
- ^{xxxiii} Lisbona R, Derbekyan V, Novales-Diaz JA. Scintigraphic evidence of pulmonary vascular occlusion in sickle cell disease. *J Nucl Med* 1997;38:1151–1153.
- ^{xxxiv} Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. Cooperative Study of Sickle Cell Disease. *Blood* 1994;84:643–649.
- ^{xxxv} Vichinsky EP, Styles LA, Colangelo LH, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. *Blood* 1997;89:1787–1792.
- ^{xxxvi} Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. *N Engl J Med* 2004;350:886–895.
- ^{xxxvii} Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. *Br J Haematol* 2006;134:109–115.
- ^{xxxviii} De Castro LM, Jonassaint JC, Graham FL, et al. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. *Am J Hematol* 2008;83:19–25.
- ^{xxxix} Barnett CF, Hsue PY, Machado RF. Pulmonary hypertension: an increasingly recognized complication of hereditary hemolytic anemias and HIV infection. *JAMA* 2008;299:324–331.
- ^{xl} Kato GJ, Hsieh M, Machado R, et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. *Am J Hematol* 2006;81:503–510.
- ^{xli} Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. *Blood* 2006;107:2279–2285.

Additional References from Appendix

42. Powell RW, Levine GL, Yang YM, et al. Acute splenic sequestration crisis in sickle cell disease: early detection and treatment. *J Pediatr Surg* 1992;27:215–219.
43. Topley JM, Rogers DW, Stevens MC, et al. Acute splenic sequestration and hypersplenism in the first five years in homozygous sickle cell disease. *Arch Dis Child* 1981;56:765–769.
44. Goldstein AR, Anderson MJ, Serjeant GR. Parvovirus associated aplastic crisis in homozygous sickle cell disease. *Arch Dis Child* 1987;62:585–588.
45. Rao SP, Miller ST, Cohen BJ. Transient aplastic crisis in patients with sickle cell disease. B19 parvovirus studies during a 7-year period. *Am J Dis Child* 1992;146:1328–1330.
46. Smith-Whitley K, Zhao H, Hodinka RL, et al. Epidemiology of human parvovirus B19 in children with sickle cell disease. *Blood* 2004;103:422–427.
47. Zimmerman SA, Davis JS, Schultz WH, et al. Subclinical parvovirus B19 infection in children with sickle cell anemia. *J Pediatr Hematol Oncol* 2003;25:387–389.
48. King KE, Shirey RS, Lankiewicz MW, et al. Delayed hemolytic transfusion reaction in sickle cell disease: simultaneous destruction of recipients' red cells. *Transfusion* 1997;37:376–381.
49. Win N, Doughty H, Telfer P, et al. Hyperhemolytic transfusion reaction in sickle cell disease. *Transfusion* 2001;41:323–328.
50. Danzer CS. The cardio-thoracic ratio: an index of cardiac enlargement. *Am J Med Sci* 1919;157:513–521.

-
51. Flowers NC, Horan LG. Hypertrophy and infarction: subtle signs of right ventricular enlargement and their relative importance. In: Schlant RC, Hurst JW, editors. *Advances in electrocardiography*. New York: Grune & Stratton; 1972.
 52. Romhilt DW, Bove KE, Norris RJ, et al. A critical appraisal of the electrocardiographic criteria for the diagnosis of left ventricular hypertrophy. *Circulation* 1969;40:185–196.
 53. Surawicz B, Knilans TK, editors. *Chou's electrocardiography in clinical practice*, 5th edition. Philadelphia, PA: WB Saunders Co.; 2001.
 54. Triulzi M, Gillam LD, Gentile R, et al. Normal cross-sectional echocardiographic values: linear dimensions and chamber area. *Echocardiography* 1984;1:403–426.
 55. Willerson JT, Cohn JN, Wellens HJJ, Holmes DR, editors. *Cardiovascular medicine*, 3rd edition. Philadelphia, PA: Churchill Livingstone; 2007.
 56. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. *N Engl J Med* 1994;331:1564–1575.
 57. Epstein SE, Henry WL, Clark CE, et al. Asymmetric septal hypertrophy. *Ann Intern Med* 1974;81:650–680.
 58. Humphrey PA, Dehner LP, Pfeifer, JD. *Washington manual of surgical pathology*. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. 816 p.
 59. Huwez FU, Houston AB, Watson J, et al. Age and body surface area related to normal upper and lower limits of M mode echocardiographic measurements and left ventricular volume and mass from infancy to early adulthood. *Br Heart J* 1994;72:276–280.
 60. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *J Am Soc Echocardiogr* 2005;18:1440–1463.
 61. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. *J Am Coll Cardiol* 2003;42:1687–1713.
 62. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. *N Engl J Med* 2003;348:295–303.
 63. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. *Circulation* 1996;93:841–842.
 64. Sachdev V, Machado RF, Shizukuda Y, et al. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. *J Am Coll Cardiol* 2007;49:472–479.
 65. Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. *Br Heart J* 1993;70:357–362.
 66. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* 2003;42:1206–1252.
 67. Netea RT, Lenders JW, Smits P, et al. Influence of body and arm position on blood pressure readings: an overview. *J Hypertens* 2003;21:237–241.
 68. Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. *Am J Med* 1997;102:171–177.
 69. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1. Blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. *Hypertension* 2005;45:142–161.
 70. Report of the Second Task Force on Blood Pressure Control in Children—1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. *Pediatrics* 1987;79:1–25.

-
71. Criley JM, Lewis KB, Humphries JO, et al. Prolapse of the mitral valve: clinical and cine-angiocardigraphic findings. *Br Heart J* 1966;28:488–496.
 72. Gilbert BW, Schatz RA, VonRamm OT, et al. Mitral valve prolapse. Two-dimensional echocardiographic and angiographic correlation. *Circulation* 1976;54:716–723.
 73. Alpert, JS, Thygesen, K, Antman E, et al. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *J Am Coll Cardiol* 2000;36:959–969.
 74. Andersen JA, Hansen BF. The value of the nitro-BT method in fresh myocardial infarction. Frequency and location of fresh myocardial infarction in a consecutive series of autopsies. *Am Heart J* 1973;85:611–619.
 75. Feldman S, Glagov S, Wissler RW, et al. Postmortem delineation of infarcted myocardium. Coronary perfusion with nitro blue tetrazolium. *Arch Pathol Lab Med* 1976;100:55–58.
 76. Nayar A, Olsen EG. The use of the basic fuchsin stain in the recognition of early myocardial ischaemia. *Cardiovasc Res* 1974;8:391–394.
 77. Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. *J Am Coll Cardiol* 2007;50:2173–2195.
 78. de Onis M, Yip R. The WHO growth chart: historical considerations and current scientific issues. *Bibl Nutr Dieta* 1996;53:74–89.
 79. Wang WC, Morales KH, Scher CD, et al. Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. *J Pediatr* 2005;147:244–247.
 80. Boland GW, Slater G, Lu DS, et al. Prevalence and significance of gallbladder abnormalities seen on sonography in intensive care patients. *Am J Roentgenol* 2000;174:973–977.
 81. Chatziioannou SN, Moore WH, Ford PV, et al. Hepatobiliary scintigraphy is superior to abdominal ultrasonography in suspected acute cholecystitis. *Surgery* 2000;127:609–613.
 82. Johnson CS. The liver in sickle cell disease. In: Okpala IE, editor. *Practical Management of Haemoglobinopathies*. Oxford: Blackwell Publishing Ltd.; 2004. p 120–129.
 83. Magid D, Fishman EK, Charache S, et al. Abdominal pain in sickle cell disease: The role of CT. *Radiology* 1987;163:325–328.
 84. Ralls PW, Colletti PM, Lapin SA, et al. Real-time sonography in suspected acute cholecystitis. Prospective evaluation of primary and secondary signs. *Radiology* 1985;155:767–771.
 85. Singer AJ, McCracken G, Henry MC, et al. Correlation among clinical, laboratory, and hepatobiliary scanning findings in patients with suspected acute cholecystitis. *Ann Emerg Med* 1996;28:267–272.
 86. Jain R. Biliary sludge: when should it not be ignored. *Curr Treat Options Gastroenterol* 2004;7:105–109.
 87. Rubens DJ. Hepatobiliary imaging and its pitfalls. *Radiol Clin North Am* 2004;42:257–278.
 88. Schubert, TT. Hepatobiliary system in sickle cell disease. *Gastroenterology* 1986;90:2013–2021.
 89. Shea JA, Berlin JA, Escarce JJ, et al. Revised estimates of diagnostic test sensitivity and specificity in suspected biliary tract disease. *Arch Intern Med* 1994;154:2573–2581.
 90. Ware RE, Schultz WH, et al. Diagnosis and management of common bile duct stones in patients with sickle hemoglobinopathies. *J Pediatr Surg* 1992;27(5):572–575.
 91. Banerjee S, Owen C, Chopra S. Sickle cell hepatopathy. *Hepatology* 2001;33:1021–1028.
 92. Buchanan GR, Glader BE. Benign course of extreme hyperbilirubinemia in sickle cell anemia: analysis of six cases. *J Pediatr* 1977; 91: 21–24.
 93. Johnson CS, Omata M, Tong MJ, et al. Liver involvement in sickle cell disease. *Medicine (Baltimore)* 1985;64:349–356.
 94. Shao SH, Orringer EP. Sickle cell intrahepatic cholestasis: approach to a difficult problem. *Am J Gastroenterol* 1995;90:2048–2050.
 95. Stéphan JL, Merpit-Gonon E, Richard O, et al. Fulminant liver failure in a 12-year-old girl with sickle cell anaemia: favourable outcome after exchange transfusions. *Eur J Pediatr* 1995;154:469–471.
 96. Balthazar EJ, Robinson DL, Megibow AJ, et al. Acute pancreatitis: value of CT in establishing prognosis. *Radiology* 1990;174:331–336.
 97. Marshall JB. Acute pancreatitis. A review with an emphasis on new developments. *Arch Intern Med* 1993;153:1185–1198.

-
98. Ranson JH. Etiological and prognostic factors in human acute pancreatitis: a review. *Am J Gastroenterol* 1982;77:633–638.
 99. Steinberg W, Tenner S. Acute pancreatitis. *N Engl J Med* 1994;330:1198–1210.
 100. Ventrucci M. Update on laboratory diagnosis and prognosis of acute pancreatitis. *Dig Dis* 1993;11:189–196.
 101. Boyer TD, Wright TL, Manns MP, Zakim D, editors. *Zakim & Boyer's Hepatology: a textbook of liver disease*, 5th edition. Philadelphia, PA: Saunders Elsevier; 2006. pp 627–733.
 102. Schiff ER, Sorrell MF, Maddrey WC, editors. *Schiff's Diseases of the Liver*, 10th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2007. pp 709–874.
 103. Almeida A, Roberts I. Bone involvement in sickle cell disease. *Br J Haematol* 2005;129:482–490.
 104. Bohrer SP. Bone changes in the extremities in sickle cell anemia. *Semin Roentgenol* 1987;22:176–185.
 105. Ficat RP. Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment. *J Bone Joint Surg Br* 1985;67:3–9.
 106. Powars DR. Sickle cell anemia and major organ failure. *Hemoglobin* 1990;14:573–598.
 107. Steinberg ME, Steinberg DR. Classification systems for osteonecrosis: an overview. *Orthop Clin N Am* 2004;35:273–283.
 108. Almeida A, Roberts I. Bone involvement in sickle cell disease. *Br J Haematol* 2005;129:482–490.
 109. Olivieri I, Scarano E, Padula A, et al. Dactylitis, a term for different digit diseases. *Scand J Rheumatol* 2006;35:333–340.
 110. Worrall VT, Butera V. Sickle-cell dactylitis. *J Bone Joint Surg Am* 1976;58:1161–1163.
 111. Black J, Baharestani M, Cuddigan J, et al. National Pressure Ulcer Advisory Panel's updated pressure ulcer staging system. *Dermatol Nurs* 2007;19:343–350.
 112. Halabi-Tawil M, Lionnet F, Girot R, et al. Sickle cell leg ulcers: a frequently disabling complication and marker of severity. *Br J Dermatol* 2008;158:339–344.
 113. Koshy M, Entsuah R, Koranda A, et al. Leg ulcers in patients with sickle cell disease. *Blood* 1989;74:1403–1408.
 114. Nolan VG, Adewoye A, Baldwin C, et al. Sickle cell leg ulcers: association with haemolysis and SNPs in *Klotho*, *TEK* and genes of the TGF-beta/BMP pathway. *Br J Haematol* 2006;133:570–578.
 115. Dorwart BB, Gabuzda TG. Symmetric myositis and fasciitis: a complication of sickle cell anemia during vasoocclusion. *J Rheumatol* 1985;12:590–595.
 116. Manci EA, Maisel DA, Conrad ME. Systemic necrotizing vasculitis in sickle cell disease. *Am J Hematol* 1987;26:93–96.
 117. Valeriano-Marcet J, Kerr LD. Myonecrosis and myofibrosis as complications of sickle cell anemia. *Ann Intern Med* 1991;115:99–101.
 118. David R, Barron BJ, Madewell JE. Osteomyelitis, acute and chronic. *Radiol Clin North Am* 1987;25:1171–1201.
 119. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. *World Health Organ Tech Rep Ser* 1994;843:1–129.
 120. Gordon CM, Baim S, Bianchi ML, et al. Special Report on the 2007 Pediatric Position Development Conference of the International Society for Clinical Densitometry. *South Med J* 2008;101:740–743.
 121. Sarrai M, Duroseau H, D'Augustine J, et al. Bone mass density in adults with sickle cell disease. *Br J Haematol* 2007;136:666–672.
 122. Specker BL, Schoenau E. Quantitative bone analysis in children: current methods and recommendations. *J Pediatr* 2005;146:726–731.
 123. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. *Br J Haematol* 2004;127:127–139.
 124. Writing Group for the ISCD Position Development Conference. Diagnosis of osteoporosis in men, premenopausal women, and children. *J Clin Densitom* 2004;7:17–26.
 125. Adams RJ, Brambilla DJ, Granger S, et al. Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. *Blood* 2004;103:3689–3694.
 126. Bulas DI, Jones A, Seibert JJ, et al. Transcranial Doppler (TCD) screening for stroke prevention in sickle cell anemia: pitfalls in technique variation. *Pediatr Radiol* 2000;30:733–738.
 127. McCarville MB, Li C, Xiong X, et al. Comparison of transcranial Doppler sonography with and without imaging in the evaluation of children with sickle cell anemia. *AJR Am J Roentgenol* 2004;183:1117–1122.

-
128. Wolf P. Basic principles of the ILAE syndrome classification. *Epilepsy Res* 2006;70 Suppl 1:S20–26.
 129. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. *Epilepsia* 1989;30:389–399.
 130. Kohrman MH. What is epilepsy? Clinical perspectives in the diagnosis and treatment. *J Clin Neurophysiol* 2007;24:87–95.
 131. Dhar S, Tremmel M, Mocco J, et al. Morphology parameters for intracranial aneurysm rupture risk assessment. *Neurosurgery* 2008;63:185–196.
 132. Preul MC, Cendes F, Just N, et al. Intracranial aneurysms and sickle cell anemia: multiplicity and propensity for the vertebrobasilar territory. *Neurosurgery* 1998;42:971–977.
 133. Debaun MR, Derdeyn CP, McKinstry RC III. Etiology of strokes in children with sickle cell anemia. *Ment Retard Dev Disabil Res Rev* 2006;12:192–199.
 134. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. *Blood* 1998;91:288–294.
 135. Switzer JA, Hess DC, Nichols FT, et al. Pathophysiology and treatment of stroke in sickle-cell disease: present and future. *Lancet Neurol* 2006;5:501–512.
 136. Dobson SR, Holden KR, Nietert PJ, et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. *Blood* 2002;99:3144–3150.
 137. Houkin K, Nakayama N, Kuroda S, et al. Novel magnetic resonance angiography stage grading for moyamoya disease. *Cerebrovasc Dis* 2005;20:347–354.
 138. Moser FG, Miller ST, Bello JA, et al. The spectrum of brain abnormalities in sickle cell disease: A report from the Cooperative Study of Sickle Cell Disease. *AJNR Am J Neuroradiol* 1996;17:965–972.
 139. Nagpal KC, Asdourian G, Goldbaum M, et al. Angioid streaks and sickle haemoglobinopathies. *Br J Ophthalmol* 1976;60:31–34.
 140. Asdourian G, Nagpal KC, Goldbaum M, et al. Evolution of the retinal black sunburst in sickling haemoglobinopathies. *Br J Ophthalmol* 1975;59:710–716.
 141. McLeod DS, Goldberg MF, Luty GA. Dual-perspective analysis of vascular formations in sickle cell retinopathy. *Arch Ophthalmol* 1993;111:1234–1245.
 142. Romayananda N, Goldberg MF, Green WR. Histopathology of sickle cell retinopathy. *Trans Am Acad Ophthalmol Otolaryngol* 1973;77:652–676.
 143. Nagpal KC, Asdourian GK, Goldbaum MH, et al. The conjunctival sickling sign, hemoglobin S, and irreversibly sickled erythrocytes. *Arch Ophthalmol* 1977;95:808–811.
 144. Paton D. The conjunctival sign of sickle-cell disease. *Arch Ophthalmol* 1961;66:90–94.
 145. Paton D. The conjunctival sign of sickle-cell disease. Further observations. *Arch Ophthalmol* 1962;68:627–632.
 146. Goldberg MF. Sickled erythrocytes, hyphema, and secondary glaucoma: I. The diagnosis and treatment of sickled erythrocytes in human hyphemas. *Ophthalmic Surg* 1979;10:17–31.
 147. Goldberg MF, Dizon R, Raichand M. Sickled erythrocytes, hyphema, and secondary glaucoma: II. Injected sickle cell erythrocytes into human, monkey, and guinea pig anterior chambers: the induction of sickling and secondary glaucoma. *Ophthalmic Surg* 1979;10:32–51.
 148. Goldberg MF, Dizon R, Raichand M, et al. Sickled erythrocytes, hyphema, and secondary glaucoma: III. Effects of sickle cell and normal human blood samples in rabbit anterior chambers. *Ophthalmic Surg* 1979;10:52–61.
 149. Goldberg MF. Sickled erythrocytes, hyphema, and secondary glaucoma: IV. The rate and percentage of sickling of erythrocytes in rabbit aqueous humor, in vitro and in vivo. *Ophthalmic Surg* 1979;10:62–69.
 150. Goldberg MF. Sickled erythrocytes, hyphema, and secondary glaucoma: V. The effect of vitamin C on erythrocyte sickling in aqueous humor. *Ophthalmic Surg* 1979;10:70–77.
 151. Goldberg MF, Dizon R, Moses VK. Sickled erythrocytes, hyphema, and secondary glaucoma: VI. The relationship between intracameral blood cells and aqueous humor pH, PO₂, and PCO₂. *Ophthalmic Surg* 1979;10:78–88.
 152. Goldberg MF, Tso MO. Sickled erythrocytes, hyphema, and secondary glaucoma: VII. The passage of sickled erythrocytes out of the anterior chamber of the human and monkey eye: light and electron microscopic studies. *Ophthalmic Surg* 1979;10:89–123.
 153. Goldberg MF. The diagnosis and treatment of sickled erythrocytes in human hyphemas. *Trans Am Ophthalmol Soc* 1978;76:481–501.

-
154. Cao J, Mathews MK, McLeod DS, et al. Angiogenic factors in human proliferative sickle cell retinopathy. *Br J Ophthalmol* 1999;83:838–846.
 155. Condon PI, Serjeant GR. Behaviour of untreated proliferative sickle retinopathy. *Br J Ophthalmol* 1980;64:404–411.
 156. Goldberg MF. Classification and pathogenesis of proliferative sickle retinopathy. *Am J Ophthalmol* 1971;71:649–665.
 157. Goldberg MF. Sickle cell retinopathy. In: Duane TD, editor. *Clinical Ophthalmology*. Hagerstown, MD: Harper and Row Publishers, Inc.; 1976. p 1–44.
 158. Goldberg MF. Retinal neovascularization in sickle cell retinopathy. *Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol* 1977;83(3 Pt 1):409–431.
 159. McLeod DS, Merges C, Fukushima A, et al. Histopathological features of neovascularization in sickle cell retinopathy. *Am. J. Ophthalmol.* 1997;124:455–472.
 160. Nagpal KC, Patrianakos D, Asdourian GK, et al. Spontaneous regression (autoinfarction) of proliferative sickle retinopathy. *Am J Ophthalmol* 1975;80:885–892.
 161. Nagpal KC, Goldberg MF, Rabb MF. Ocular manifestations of sickle hemoglobinopathies. *Surv Ophthalmol* 1977;21:391–411.
 162. Raichand M, Goldberg MF, Nagpal KC, et al. Evolution of neovascularization in sickle cell retinopathy. *Arch Ophthalmol* 1977;95:1543–1552.
 163. Brazier DJ, Gregor ZJ, Blach RK, et al. Retinal detachment in patients with proliferative sickle cell retinopathy. *Trans Ophthalmol Soc UK* 1986;105 (Pt 1):100–105.
 164. Condon PI, Serjeant GR. Ocular findings in homozygous sickle cell anemia in Jamaica. *Am J Ophthalmol* 1972;73:533–543.
 165. Condon PI, Serjeant GR. Ocular findings in hemoglobin SC disease in Jamaica. *Am J Ophthalmol* 1972;74:921–931.
 166. Durant WJ, Jampol LM, Daily M. Exudative retinal detachment in hemoglobin SC disease. *Retina* 1982;2:152–154.
 167. Jampol LM, Green JL Jr, Goldberg MF, et al. An update on vitrectomy surgery and retinal detachment repair in sickle cell disease. *Arch Ophthalmol* 1982;100:591–593.
 168. Gagliano DA, Goldberg MF. The evolution of salmon-patch hemorrhages in sickle cell retinopathy. *Arch Ophthalmol* 1989;107:1814–1815.
 169. van Meurs JC. Evolution of a retinal hemorrhage in a patient with sickle cell-hemoglobin C disease. *Arch Ophthalmol* 1995;113:1074–1075.
 170. Dana MR, Werner MS, Viana MA, et al. Spontaneous and traumatic vitreous hemorrhage. *Ophthalmology* 1993;100:1377–1383.
 171. Hassell KL, Eckman JR, Lane PA. Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. *Am J Med* 1994;96:155–162.
 172. Perronne V, Roberts-Harewood M, Bachir D, et al. Patterns of mortality in sickle cell disease in adults in France and England. *Hematol J* 2002;3:56–60.
 173. Tedla FM, Friedman EA. Multiorgan failure during a sickle cell crisis in sickle/beta-thalassemia. *Am J Kidney Dis* 2003;42:E6–8.
 174. Ballas SK. The sickle cell painful crisis in adults: phases and objective signs. *Hemoglobin* 1995;19:323–333.
 175. Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. *Blood* 2000;95:1130–1136.
 176. Dampier C, Ely E, Brodecki D, et al. Home management of pain in sickle cell disease: a daily diary study in children and adolescents. *J Pediatr Hematol Oncol* 2002;24:643–647.
 177. Jacob E, Miaskowski C, Savedra M, et al. Changes in intensity, location, and quality of vaso-occlusive pain in children with sickle cell disease. *Pain* 2003;102:187–193.
 178. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. *Ann Intern Med* 2008;148:94–101.
 179. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. *Anesthesiology* 2006;104:570–587.
 180. Compton P, Athanasos P, Elashoff D. Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: a preliminary study. *J Pain* 2003;4:511–519.

-
181. Elander J, Lusher J, Bevan D, et al. Understanding the causes of problematic pain management in sickle cell disease: evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. *J Pain Symptom Manage* 2004;27:156–169.
 182. Lusher J, Elander J, Bevan, D, et al. Analgesic addiction and pseudoaddiction in painful chronic illness. *Clin J Pain* 2006;22:316–324.
 183. Mercadante S, Ferrera P, Villari P, et al. Hyperalgesia: an emerging iatrogenic syndrome. *J Pain Symptom Manage* 2003;26:769–775.
 184. Ballas SK, Reyes PF. Peripheral neuropathy in adults with sickle cell disease. *Am J Pain Management* 1997;7:53–58.
 185. Baron R. Mechanisms of disease: neuropathic pain--a clinical perspective. *Nat Clin Pract Neurol* 2006;2:95–106.
 186. Campbell JN. Nerve lesions and the generation of pain. *Muscle Nerve* 2001;24:1261–1273.
 187. Hansson P, Backonja M, Bouhassira D. Usefulness and limitations of quantitative sensory testing: clinical and research application in neuropathic pain states. *Pain* 1007;129:256–259.
 188. Ossipov MH, Lai J, Malan TP Jr., et al. Spinal and supraspinal mechanisms of neuropathic pain. *Ann NY Acad Sci* 2000;909:12–24.
 189. Woolf CJ. Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. *Life Sci* 2004;74:2605–2610.
 190. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med* 1994;149:818–824.
 191. Johnson CS. The acute chest syndrome. *Hematol Oncol Clin North Am* 2005;19:857–879.
 192. Rackoff WR, Kunkel N, Silber JH, et al. Pulse oximetry and factors associated with hemoglobin oxygen desaturation in children with sickle cell disease. *Blood* 1993;81:3422–3427.
 193. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. *N Engl J Med* 2000;342:1855–1865.
 194. Vichinsky E, Williams R, Das M, et al. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. *Blood* 1994;83:3107–3112.
 195. Bacharier LB, Boner A, Carlsen KH, et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. *Allergy* 2008;63:5–34.
 196. Boyd JH, Macklin EA, Strunk RC, et al. Asthma is associated with increased mortality in individuals with sickle cell anemia. *Haematologica* 2007;92:1115–1118.
 197. Expert Panel Report 2007 Guidelines for the Diagnosis and Management of Asthma [EPR 2007] NIH Publication 07-4051. Bethesda, MD: US Department of Health and Human Services. NIH: NHLBI National Asthma Education and Prevention Program. August 28, 2007.
 198. Horner CC, Strunk RC. Age-related changes in the asthmatic phenotype in children. *Curr Opin Pediatr* 2007;19:295–299.
 199. National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute, National Institutes of Health. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma; Full Report 2007. Bethesda, MD: US Dept of Health and Human Services; August 2007. NIH publication 07-4051.
 200. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J* 2004;23:932–946.
 201. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007. Available from: <http://www.goldcopd.org>.
 202. Snider GL. Nosology for our day: its application to chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2003;167:678–683.
 203. Blake M, Crapo RO (Co-chairpersons). Lung function testing: selection of reference values and interpretative strategies. *Am Rev Respir Dis* 1991;144:1202–1218.
 204. Klings ES, Wyszynski DF, Nolan VG, et al. Abnormal pulmonary function in adults with sickle cell anemia. *Am J Resp Crit Care Med* 2006;173:1264–1269.
 205. MacLean JE, Atenafu E, Kirby-Allen M, et al. Longitudinal decline in lung volume in a population of children with sickle cell disease. *Am J Resp Crit Care Med* 2008;178:1055–1059.

-
206. The PIOPED investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). *JAMA* 1990;263:2753–2759.
 207. Stein PD, Fowler SE, Goodman LR, et al, for the PIOPED II Investigators. Multidetector computed tomography for acute pulmonary embolism. *N Engl J Med* 2006;354:2317–2327.
 208. Stein PD, Hull RD, Patel KC, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. *Ann Intern Med* 2004;140:589–602.
 209. Lanzarini L, Fontana A, Lucca E, et al. Noninvasive estimation of both systolic and diastolic pulmonary artery pressure from Doppler analysis of tricuspid regurgitant velocity spectrum in patients with chronic heart failure. *Am Heart J* 2002;144:1087–1094.
 210. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. *Chest* 2004;126(1 suppl):14S–34S.
 211. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2004;43(12 Suppl S):5S–12S.
 212. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 2004;8:R204–R212.
 213. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. *Lancet* 2005;365:417–430.
 214. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease. *Am J Kidney Dis* 2002;39(2 suppl 1):S76–S110.
 215. Singri N, Ahya SN, Levin ML. Acute renal failure. *JAMA* 2003;289:747–751.
 216. West MS, Wethers D, Smith J, et al. Laboratory profile of sickle cell disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell Disease. *J Clin Epidemiol* 1992;45:893–909.
 217. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976;16:31–41.
 218. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999;130:461–470.
 219. Schwartz GJ, Haycock GB, Edelmann CM Jr, et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. *Pediatrics* 1976;58:259–263.
 220. Johnson C. Renal complications of the sickle cell diseases. In: Education Program Book. Washington, DC: American Society of Hematology; 1999. p 44–50.
 221. Berger R, Billups K, Brock G, et al. Report of the American Foundation for Urologic Disease (AFUD) Thought Leader Panel for evaluation and treatment of priapism. *Int J Impot Res* 2001;13(suppl 5):S39–S43.
 222. Montague DK, Jarow J, Broderick GA, et al. American Urological Association guideline on the management of priapism. *J Urol* 2003;170(4 Pt 1):1318–1324.
 223. Rogers, ZR. Priapism in sickle cell disease. *Hematol Oncol Clin North Am* 2005;19:917–928.
 224. Dharnidharka VR, Dabbagh S, Atiyeh B, et al. Prevalence of microalbuminuria in children with sickle cell disease. *Pediatr Nephrol* 1998;12:475–478.
 225. Foucan L, Bourhis V, Bangou J, et al. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. *Am J Med* 1998;104:339–342.
 226. Guasch A, Navarrete J, Nass K, et al. Glomerular involvement in adults with sickle cell hemoglobinopathies: prevalence and clinical correlates of progressive renal failure. *J Am Soc Nephrol* 2006;17:2228–2235.
 227. Hogg RJ, Portman RJ, Milliner D, et al. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established by the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection and elimination (PARADE). *Pediatrics* 2000;105:1242–1249.
 228. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. *Am J Kidney Dis* 1999;33:1004–1010.
 229. Benador D, Benador N, Slosman DO, et al. Cortical scintigraphy in the evaluation of renal parenchymal changes in children with pyelonephritis. *J Pediatr* 1994;124:17–20.

-
230. Jakobsson B, Soderlundh S, Berg U. Diagnostic significance of ^{99m}Tc-dimercaptosuccinic acid (DMSA) scintigraphy in urinary tract infection. *Arch Dis Child* 1992;67:1338–1342.
 231. Coleman WA, Furth FW. Splenic infarction in a patient with sickle-cell-hemoglobin-C disease; report of a case occurring following air travel. *AMA Arch Intern Med* 1956;98: 247–249.
 232. Jama AH, Salem AH, Dabbous IA. Massive splenic infarction in Saudi patients with sickle cell anemia: a unique manifestation. *Am J Hematol* 2002;69:205–209.
 233. Stock AE. Splenic infarction associated with high altitude flying and sickle cell trait. *Ann Intern Med* 1956;44:554–556.
 234. Pearson HA, Gallagher D, Chilcote R, et al. Developmental pattern of splenic dysfunction in sickle cell disorders. *Pediatrics* 1985;76:392–397.
 235. Pearson HA, McIntosh S, Ritchey AK, et al. Developmental aspects of splenic function in sickle cell diseases. *Blood* 1979;53:358–365.
 236. Emond AM, Morais P, Venugopal S, et al. Role of splenectomy in homozygous sickle cell disease in childhood. *Lancet* 1984;323: 88–91.
 237. Chien S, King RG, Kaperonis AA, et al. Viscoelastic properties of sickle cells and hemoglobin. *Blood Cells* 1982;8:53–64.
 238. Chien S, Usami S, Bertles JF. Abnormal rheology of oxygenated blood in sickle cell anemia. *J Clin Invest* 1970;49:623–634.
 239. Jan K, Usami S, Smith JA. Effects of transfusion on rheological properties of blood in sickle cell anemia. *Transfusion* 1982;22:17–20.
 240. Johnson CS. Arterial blood pressure and hyperviscosity in sickle cell disease. *Hematol Oncol Clin North Am* 2005;19:827–837.
 241. Lee ES, Chu PC. Reverse sequestration in a case of sickle crisis. *Postgrad Med J* 1996;72:487–488.
 242. Mohandas N, Hebbel RP. Erythrocyte deformability, fragility and rheology. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, editors. *Sickle Cell Disease*. New York: Raven Press; 1994. pp 205–216.
 243. Talano JA, Hillery CA, Gottschall JL, et al. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. *Pediatrics* 2003;111(6 Pt 1):e661–e665.
 244. Karam LB, Disco D, Jackson SM, et al. Liver biopsy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels. *Pediatr Blood Cancer* 2008;50:62–65.
 245. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. *Blood* 2005;105:855–861.